01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:33 , Jun 17, 2019 |  BC Extra  |  Company News

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy. The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and...
22:15 , Jun 17, 2019 |  BC Extra  |  Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on...
20:40 , Jun 3, 2019 |  BC Extra  |  Company News

Patients, payers await pricing plans for bluebird's first approved gene therapy

bluebird gained the first European approval of Zynteglo, a β-thalassemia gene therapy Monday, but payers and patients will have to wait until the end of next week for the company to announce pricing and commercialization...
17:49 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

CD34-positive melanocyte stem cells for demyelination diseases

DISEASE CATEGORY: Neurology INDICATION: Neurology Cell culture and mouse studies suggest CD34-positive melanocyte stem cells could help treat demyelination diseases. In primary mouse dorsal root ganglion (DRG) neurons from a mouse model of CNS demyelination,...
21:44 , May 9, 2019 |  BC Extra  |  Company News

bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020. In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
13:29 , Mar 29, 2019 |  BC Extra  |  Company News

CHMP backs approval of bluebird's beta-thalassemia gene therapy

EMA's CHMP recommended conditional approval of bluebird's gene therapy Zynteglo to treat transfusion-dependent β-thalassemia. The therapy is not yet approved in any territory. The committee backed Zynteglo's approval in patients ages 12 and older who...